Pharmacokinetics of 1-(2-Fluoro-5-methyl-β-L-arabinofuranosyl) uracil in woodchucks

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2184-2187

  Witcher, Jennifer Wright ^a   Boudinot, F Douglas ^a   Baldwin, Betty H ^b   Ascenzi, Mary A ^b   Tennant, Bud C ^b   Du, Jin F ^a   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 FLUORO 5 METHYL BETA L ARABINOFURANOSYL)URACIL; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG UPTAKE; DRUG URINE LEVEL; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030840530     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2184     Document Type: Article

References (20)

1. Blumberg, B. S., B. J. S. Gerstley, D. A. Hungerford, W. T. London, and A. L. Sutnick. 1967. A serum antigen (Australia antigen) in Down's syndrome, leukemia and hepatitis. Ann. Intern. Med. 66:924-931.
2. Chu, C. K., T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S. B. Pai, G.-Q. Yao, J.-P. Sommadossi, and Y.-C. Cheng. 1995. Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B and Epstein-Barr virus. Antimicrob. Agents Chemother. 39:979-981.
3. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
4. Hoofnagle, J. H., M. Peters, K. D. Mullen, D. B. Jones, V. Rustgi, A. D. Bisceglie, C. Hallahan, Y. Park, C. Meschievitz, and E. A. Jones. 1988. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325.
5. Institute of Laboratory Animal Resources, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
6. Korba, B. E., F. Wells, B. C. Tennant, P. J. Cote, and J. L. Gerin. 1987. Lymphoid cells in the spleens of woodchuck hepatitis virus-infected woodchucks are a site of active viral replication. J. Virol. 61:1318-1324.
7. Korba, B. E., E. J. Gowans, F. V. Wells, B. C. Tennant, R. Clarke, and J. L. Gerin. 1988. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. Virology 165:172-181.
8. Lieberman, H. M., W. W. Tung, and D. A. Shafritz. 1987. Splenic replication of hepatitis B virus in the chimpanzee chronic carrier. J. Med. Virol. 21:347-359.
9. Rajagopalan, P., F. D. Boudinot, C. K. Chu, B. C. Tennant, B. H. Baldwin, and R. F. Schinazi. 1996. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob. Agents Chemother. 40:642-645.
10. Rajagopalan, P., F. D. Boudinot, C. K. Chu, B. C. Tennant, B. H. Baldwin, and R. F. Schinazi. 1996. Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, in woodchucks (Marmota monax). Antiviral Chem. Chemother. 7:65-70.
11. Rocci, M. L., and W. J. Jusko. 1983. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:203-216.
12. Shanmaganathan, K., T. Koudriakova, S. Nampalli, J. M. Gallo, and C. K. Chu. 1994. Enhanced brain delivery of an anti-HIV nucleoside 2-F-ara-ddI by xanthine oxidase mediated biotransformation. J. Med. Chem. 37:821-827.
13. Shimoda, T., T. Shikata, T. Karasawa, S. Tzukaghosi, M. Yosimura, and I. Sakurai. 1981. Light microscopic localization of hepatitis B virus antigens in the human pancreas. Gastroenterology 81:998-1005.
14. Summers, J., J. M. Smolec, and R. Snyder. 1978. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc. Natl. Acad. Sci. USA 75:4533-4537.
15. Szmuness, W. 1978. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog. Med. Virol. 24:40-69.
16. Tann, C. H., P. R. Brodfuehrer, S. P. Brundidge, C. Sapino, Jr., and H. G. Howell. 1985. Fluorocarbohydrates in synthesis. An efficient synthesis of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil (β-FIAU) and 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-thymine (β-FMAU). J. Org. Chem. 50:3644-3647
17. Werner, B. G., J. M. Smolec, R. Snyder, and J. Summers. 1979. Serological relationship of woodchuck hepatitis virus to human hepatitis B virus. J. Virol. 32:314-322.
18. Wright, D., T. Ma, C. K. Chu, and F. D. Boudinot. 1995. Pharmacokinetics of 1-(2-deoxy-2-fluoro-5-methyl-β-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats. Pharm. Res. 12:1350-1353.
19. Wright, J. D., T. Ma, C. K. Chu, and F. D. Boudinot. 1996. Bioavailability and oral absorption site model of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl) uracil (L-FMAU) in rats. Biopharm. Drug Dispos. 17:197-207.
20. Yeh, K. C., and K. C. Kwan. 1978. A comparison of numerical integrating algorithms by trapezoidal, Lagrange and Spline approximation. J. Pharmacokinet. Biopharm. 6:79-98.